Ekso Bionics saw a significant drop in revenue during Q2 2025, primarily from delayed Enterprise Health sales, but partially offset by increased Personal device sales and reduced service costs.

Ekso Bionics reported revenue of $3.4 million for the first quarter of 2025, a decrease from $3.8 million in the same period of 2024. The net loss applicable to common stockholders was $2.9 million, or $0.12 per basic and diluted share, an improvement from a net loss of $3.4 million, or $0.20 per basic and diluted share, in the prior year. The company also improved its operating cash burn by 43%.

Ekso Bionics achieved record fourth-quarter revenue of $5.1 million, a 5% increase year-over-year, and improved its gross margin to 53%. The company also reported a net loss of $3.4 million for the quarter.

Ekso Bionics reported revenue of $4.1 million for the third quarter of 2024 and a gross margin of 53.5%. The company's net loss narrowed to $2.1 million, or $0.10 per share.

Ekso Bionics reported record revenues of $5.0 million for the second quarter of 2024, a 5% increase compared to the same period in 2023. The company achieved a gross margin of 53% and sold 37 EksoHealth devices.

Ekso Bionics reported a revenue of $3.8 million for Q1 2024, compared to $4.1 million in the same period last year. The company's gross margin increased to 52%, and the net loss decreased to $3.4 million, or $0.20 per share.

Ekso Bionics reported record annual revenue of $18.3 million in 2023, driven by strong demand for EksoHealth devices. Fourth-quarter revenue increased by 36% to $4.8 million, with a gross profit of $2.4 million and a 49% gross margin. The company sold 38 EksoHealth units in Q4 2023.

Ekso Bionics reported a strong third quarter with a 38% increase in revenue, reaching $4.6 million, driven by solid sales of EksoHealth devices and a record number of EVO unit sales. The company's gross profit also increased by 46% to $2.5 million, with a gross margin of approximately 53%.

Ekso Bionics reported record revenues of $4.7 million in Q2 2023, a 36% increase year-over-year, driven by a record number of EksoHealth device bookings. Gross profit also increased to $2.3 million, with a gross margin of approximately 48%.